1. Home
  2. Live Updates
  3. Opdivo monotherapy

Live Breaking News & Updates on Opdivo monotherapy

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression =1%

Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients' risk of disease recurrence or death compared to placebo Opdivo

Japan , Norway , Taiwan , Iceland , United-states , China , Liechtenstein , South-korea , American , Dana-walker , Fred-witjes , Opdivo-monotherapy

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatm

Approval based on Phase 3 CheckMate -274 trial results showing that adjuvant treatment with Opdivo significantly reduced patients’ risk of disease recurrence or death compared to placeboOpdivo is now the first and only adjuvant immunotherapy option approved in this setting in the European UnionDecision marks the thi.

China , Norway , Iceland , Japan , United-states , Liechtenstein , American , Dana-walker , Fred-witjes , Opdivo-monotherapy , Alex-filicevas , Company-opdivo